Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Toshiyoshi Fujiwara

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5377-6051; OpenAlex author ID A5068717107, A5110162610. Sources: OpenAlex.

Their work

Papers
32 (first author 0, last author 29)
Trials
0
Grants
0
Labs led
1
Collaborators
51
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 5 papers · 2023: 3 papers · 2024: 4 papers · 2025: 8 papers · 2026: 6 papers

Papers 32

  1. Turning pancreatic cancer from cold to hot: the promise of a p53-expressing oncolytic adenovirus (OBP-702). Last author DOI 10.1007/s10147-026-02991-7↗
  2. Mitochondrial inhibition enhances the sensitivity of pancreatic ductal adenocarcinoma cells to oncolytic adenovirus. Last author DOI 10.1016/j.omton.2026.201180↗
  3. p53-armed oncolytic adenovirus induces apoptosis in pancreatic cancer-associated stellate cells via macropinocytosis. Last author DOI 10.1038/s41417-025-00989-3↗
  4. Impact of Cirrhosis Outcome Risk Estimator Score on Outcomes Following Pancreatectomy for Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.21873/invivo.14364↗
  5. Predictive Nomogram for Recurrence After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Last author DOI 10.3390/cancers18071181↗
  6. Multidisciplinary Treatment for Advanced Pancreatic Adenocarcinoma Arising from Esophageal Heterotopic Pancreas in a Young Adult: A Case Report. Last author DOI 10.70352/scrj.cr.26-0088↗
  7. Cancer-associated fibroblasts promote pro-tumor functions of neutrophils in pancreatic cancer via IL-8: potential suppression by pirfenidone. Last author DOI 10.1007/s00262-025-03946-z↗
  8. Robotic posterior radical antegrade modular pancreatosplenectomy for left-sided pancreatic cancer using the ligament of Treitz first approach: A case report an… Last author DOI 10.1016/j.ijscr.2025.111782↗
  9. Gemcitabine-induced neutrophil extracellular traps via interleukin-8-CXCR1/2 pathway promote chemoresistance in pancreatic cancer. Last author DOI 10.1038/s41416-025-03192-1↗
  10. Precise stratification of prognosis in pancreatic ductal adenocarcinoma patients based on pre- and postoperative genomic information. Last author DOI 10.1186/s12935-025-03894-9↗
  11. Impact of Neoadjuvant Chemotherapy with Gemcitabine Plus S-1 in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/cancers17203287↗
  12. Prognosis Prediction Model After Upfront Surgery for Resectable Pancreatic Ductal Adenocarcinoma: A Multicenter Study (OS-HBP-2). Last author DOI 10.3390/cancers17223694↗
  13. [Development of Oncolytic Virus Immunotherapy to Improve the Immunosuppressive Microenvironment in Pancreatic Cancer]. Last author PMID 40420372↗
  14. [Development of Immunotherapy to Target Autophagy‒Dependent Immune Evasion in Pancreatic Cancer]. Last author PMID 41139971↗
  15. BNCT pancreatic cancer treatment strategy with glucose-conjugated boron drug. Co-author DOI 10.1016/j.biomaterials.2024.122605↗
  16. Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. Last author DOI 10.1038/s41416-024-02583-0↗
  17. Author Correction: Long-term activation of anti-tumor immunity in pancreatic cancer by a p53-expressing telomerase-specific oncolytic adenovirus. Last author DOI 10.1038/s41416-024-02850-0↗
  18. Robot-Assisted Pancreaticoduodenectomy Using the Anterior Superior Mesenteric Artery-First Approach for Pancreatic Cancer. Last author DOI 10.1245/s10434-024-16305-6↗
  19. Oncolytic virus-mediated reducing of myeloid-derived suppressor cells enhances the efficacy of PD-L1 blockade in gemcitabine-resistant pancreatic cancer. Last author DOI 10.1007/s00262-022-03334-x↗
  20. Role of Surgery for Pancreatic Ductal Adenocarcinoma in the Era of Multidisciplinary Treatment. Last author DOI 10.3390/jcm12020465↗
  21. [Therapeutic Effect of Oncolytic Adenovirus on Pancreatic Cancer Stroma]. Last author PMID 38035844↗
  22. Oncolytic virus-mediated p53 overexpression promotes immunogenic cell death and efficacy of PD-1 blockade in pancreatic cancer. Last author DOI 10.1016/j.omto.2022.09.003↗
  23. Feasibility of local therapy for recurrent pancreatic cancer. Last author DOI 10.1016/j.pan.2022.05.004↗
  24. A Systematic Review of Minimally Invasive Versus Open Radical Antegrade Modular Pancreatosplenectomy for Pancreatic Cancer. Last author DOI 10.21873/anticanres.15523↗
  25. Possibility of Neoadjuvant Treatment for Radiologically Judged Resectable Pancreatic Cancer. Last author DOI 10.3390/jcm11226792↗
  26. [Telomerase-Specific Oncolytic Adenovirus Expressing p53 Gene Stimulating CD8+ Memory T Cells in Pancreatic Cancer]. Last author PMID 36281608↗
  27. Targeting neutrophil extracellular traps with thrombomodulin prevents pancreatic cancer metastasis. Last author DOI 10.1016/j.canlet.2020.10.015↗
  28. Usefulness of Middle Colic Artery Transposition Technique for Hepatic Arterial Reconstruction in Conversion Surgery for an Initially Unresectable, Locally Adva… Last author DOI 10.18926/amo/62410↗
  29. Oncolytic Virus-Mediated Targeting of the ERK Signaling Pathway Inhibits Invasive Propensity in Human Pancreatic Cancer. Last author DOI 10.1016/j.omto.2020.03.016↗
  30. The epithelial-to-mesenchymal transition induced by tumor-associated macrophages confers chemoresistance in peritoneally disseminated pancreatic cancer. Last author DOI 10.1186/s13046-018-0981-2↗
  31. Phase II clinical trial of peptide cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Co-author DOI 10.1111/cas.13113↗
  32. Predictive biomarkers for the efficacy of peptide vaccine treatment: based on the results of a phase II study on advanced pancreatic cancer. Co-author DOI 10.1186/s13046-017-0509-1↗

Closest collaborators

The 25 strongest of 51 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shinji Kuroda · 16 shared papers, 2018–2026 · strength 2.96
  2. Kosei Takagi · 13 shared papers, 2021–2026 · strength 2.92
  3. Kazuya Yasui · 13 shared papers, 2021–2026 · strength 2.84
  4. Ryuichi Yoshida · 16 shared papers, 2018–2026 · strength 2.74
  5. Yuzo Umeda · 13 shared papers, 2017–2026 · strength 1.96
  6. Yasuo Nagai · 7 shared papers, 2023–2026 · strength 1.55
  7. Takeyoshi Nishiyama · 6 shared papers, 2024–2026 · strength 1.50
  8. Masashi Hashimoto · 6 shared papers, 2022–2026 · strength 1.21
  9. Yoshinori Kajiwara · 4 shared papers, 2022–2026 · strength 0.78
  10. Kazuyuki Matsumoto · 3 shared papers, 2025 · strength 0.77
  11. Takehiro Okabayashi · 3 shared papers, 2022–2026 · strength 0.61
  12. Kenta Sui · 3 shared papers, 2022–2026 · strength 0.61
  13. Ryohei Shoji · 3 shared papers, 2020–2026 · strength 0.58
  14. Kanto Suemori · 2 shared papers, 2025 · strength 0.45
  15. Yuki Fujii · 2 shared papers, 2025 · strength 0.44
  16. Motoyuki Otsuka · 2 shared papers, 2025 · strength 0.44
  17. Tomohiko Yagi · 2 shared papers, 2025 · strength 0.42
  18. Shohei Nogi · 2 shared papers, 2025 · strength 0.42
  19. Kazuhiro Yoshida · 2 shared papers, 2021–2022 · strength 0.28
  20. Yohei Mizusawa · 1 shared paper, 2026 · strength 0.27
  21. Shigeru Horiguchi · 1 shared paper, 2025 · strength 0.25
  22. Hiroyuki Araki · 2 shared papers, 2020–2022 · strength 0.23
  23. Hiroyoshi Y. Tanaka · 1 shared paper, 2026 · strength 0.23
  24. Mitsunobu R. Kano · 1 shared paper, 2026 · strength 0.23
  25. Atsushi Masamune · 1 shared paper, 2026 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.